FRAMINGHAM (11/24/2003) - Mark Egerton, former CEO of U.K.-based Cyprotex PLC, a preclinical services company, has joined Oxagen Ltd. as its chief commercial officer and has been appointed to the board of the company. Oxagen specializes in target identification and validation in inflammatory and metabolic diseases. Meanwhile, Oxagen's former director of business development, Simon Bennett, has taken a position with Solexa Ltd., a company developing genome-sequencing technology, as its business development director.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.